DALLAS, Nov. 6 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) announced today that it will make a presentation at the Rodman & Renshaw Annual Global Investment Conference to be held November 10-12, 2008 at the New York Palace Hotel. Jeffrey B. Davis, CEO of Access is scheduled to speak on Tuesday, November 11, 2008 at 2:50 p.m. Eastern Time, and will give a corporate overview and discuss the Company's product opportunities.
The presentation will be available via webcast and can be accessed at: http://www.wsw.com/webcast/rrshq14/accp.ob. The replay can be obtained at the same link for 90 days.
ProLindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. Access believes that ProLindac's unique molecular design potentially could eliminate some of the toxic side effects seen in the currently marketed DACH platinum, Eloxatin, which has sales in excess of $2 billion.
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company
that develops and commercializes propriety products for the treatment and
supportive care of cancer patients. Access' products include Prodac(TM),
currently in Phase 2 clinical testing of patients with ovarian cancer, and
MuGard(TM) for the management of patients with mucositis. The company also
has other advanced drug delivery technologies including
Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its
proprietary nanopolymer delivery technology based on the natural vitamin
B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which
acts as an anti-angiogenesis factor and is targeted to breast cancer;
Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of
solid tumors to kill cancer cells; Alchemix, a chemotherapeuti
|SOURCE Access Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved